Semler Research Center says the US FDA caused the “complete annihilation” of its business after regulators rejected bioanalytical studies on the back of data integrity concerns.
Chinese patients’ concerns about the quality of locally made drugs are an opportunity for US manufacturers to increase market share according to the US-China Economic and Security Review Commission.
Cambrex Corporation is installing a fourth reactor suite at its High Point, NC-based facility as it continues to grow with its customers in the market, says company VP at CPhI North America.
Flamma has opened a new cGMP workshop and R&D Center in Dalian, China and is looking to add capacity at several other sites as part of its “Flamma 2020 plan.”
Aptar Pharma has acquired 20% of the US-based company, Kali Care, less than two months after inaugurating its first facility outside of France as it aims to expand globally.
DHL Global Forwarding plans to certify seven US stations in the Americas throughout 2017 with the remaining global stations slated for certification by the end of the second quarter.
Unconfirmed reports suggest Laboratory Corporation of America Holdings (LabCorp) is in talks to acquire contract research organization Pharmaceutical Product Development LLC (PPD).
Patheon could reap the benefits of President Donald Trump’s call for increased drug production in the US by upping capacity utilisation an analyst says.
Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine).
WuXi AppTec has announced that its Jinshan Shanghai-based small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility has passed its third US FDA inspection.
The cold chain solution company, CSafe, has opened a new San Juan-based service center in conjunction with the launch of its new company, CSafe Puerto Rico LLC.
Qualicaps has swapped a manufacturing technology customer for dominance of Brazil's fast growing pharmaceutical capsule market through a recent acquisition.
Nisso Soda Co. has partnered with Mutchler Pharmaceutical Ingredients to try and win a greater share of the US hydroxypropyl cellulose market months after expanding production capacity.
Biopharma logistics provider Marken has opened its newest office and warehouse in Philadelphia, which is part of a global drug distribution network comprised of 10 cGMP compliant depots and more than 40 locations around the world.
While the overall bioscience industry has seen 7.4% jobs growth between 2001 and 2012, the sector encompassing CROs and other research, testing and medical labs has grown by more than 28%, according to a new report from industry group BIO and Battelle.
The Indian Supreme Court has been asked to cancel Ranbaxy’s manufacturing license in the wake of quality problems that earned the firm a US import ban.
The US FDA is positioned to increase drug plant inspections in China after US President Barack Obama signed a $1.1tr (€881bn) budget for fiscal 2014 into law on Saturday.
US authorities will soon have a new system capable of tracking drugs from the factory floor to the pharmacy shelf after the Senate passed the “Drug Quality and Security Bill” last night.
Novo Nordisk's North American affiliate has a new President and more news from drug delivery firm Enteris - welcome to in-Pharmatechnologist.com' People on the Move.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
The full impact of Superstorm Sandy is still being assessed, but early reports suggest that the East coast contract manufacturing industry has escaped relatively unscathed.
UK-based ProTrials Research will expand a new subsidiary in a bid to meet its clients increasing demands for a wider range of multi-national clinical trials.
The USP has forged closer bonds with the Chilean Pharmacopoeia Foundation (CPF) in the latest of a series of agreements with regional drug quality groups.
